HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. 1994

A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
Department of Epidemiology and Biostatistics, University of California, San Francisco.

OBJECTIVE To examine the HIV seroconversion rate, risk factors for seroconversion, and changes in risk behavior over time in intravenous drug users (IVDU) in San Francisco, 1985-1990. METHODS Observational study. METHODS All methadone maintenance and 21-day methadone detoxification programs in San Francisco. METHODS A total of 2351 heterosexual IVDU, of whom 681 were seronegative at first visit and seen at least twice ('repeaters'). METHODS HIV seroconversion rates, risk factors for seroconversion, and changes in behavior. RESULTS The HIV seroconversion rate in repeaters was 1.9% per person-year (ppy) of follow-up [2.1% in women versus 1.7% in men (not significant); 4% in African Americans versus 1% in whites (P = 0.006); 3.9% ppy in the first third of the study, 1.2% in the second (P = 0.007), and 1.9% in the last (not significant)]. Risk factors for seroconversion were five or more sexual partners per year [hazard ratio (HR) = 2.6; P = 0.02], use of shooting gallery ever (HR = 2.9; P = 0.02), and less than 1 year (lifetime) in methadone maintenance (HR = 2.7; P = 0.02). Self-reported intravenous cocaine use fell from 33 to 15% over 5 years, shooting gallery use fell from 19 to 6%, and the proportion with five or more sexual partners fell from 25 to 10%. Bleach use rose to 75% of needle-sharers. CONCLUSIONS The 1985-1990 HIV seroconversion rate in IVDU (1.9% ppy) was comparable to that in San Francisco cohorts of homosexual men (1.4% ppy). A decline in HIV seroconversion coincided with changes in risk behavior. Stable attendance of methadone maintenance was highly protective: the seroconversion rate in subjects with 1 year or more in methadone was 12% ppy.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D003042 Cocaine An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. Cocaine HCl,Cocaine Hydrochloride,HCl, Cocaine,Hydrochloride, Cocaine
D004203 Disinfection Rendering pathogens harmless through the use of heat, antiseptics, antibacterial agents, etc.
D004866 Equipment Contamination The presence of an infectious agent on instruments, prostheses, or other inanimate articles. Contamination, Equipment,Contaminations, Equipment,Equipment Contaminations
D005006 Ethnicity A group of people with a common cultural heritage that sets them apart from others in a variety of social relationships. Ethnic Groups,Nationality,Ethnic Group,Nationalities
D005260 Female Females
D006556 Heroin Dependence Strong dependence or addiction, both physiological and emotional, upon HEROIN. Heroin Abuse,Heroin Addiction,Heroin Smoking,Abuse, Heroin,Addiction, Heroin,Dependence, Heroin,Heroin Smokings,Smoking, Heroin
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
January 1989, JAMA,
A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
February 1994, AIDS (London, England),
A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
December 1991, MMWR. Morbidity and mortality weekly report,
A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
April 2000, AIDS education and prevention : official publication of the International Society for AIDS Education,
A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
December 1991, The International journal of the addictions,
A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
February 1987, American journal of public health,
A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
November 2009, Drug and alcohol dependence,
A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
January 1988, NIDA research monograph,
A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
August 1990, American journal of public health,
A R Moss, and K Vranizan, and R Gorter, and P Bacchetti, and J Watters, and D Osmond
January 1988, Journal of psychoactive drugs,
Copied contents to your clipboard!